Durability of the BNT162b2 XBB:1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study using the id.DRIVE platform


Por: Volkman, HR, De Munter, L, Nguyen, JL, Tran, TMP, Mitratza, M, Marques, C, Choi, L, Valluri, S, Yang, JY, Antón, A, Casas, I, Conde-Sousa, E, Drikite, L, Grüner, B, Icardi, G, Ten Kate, GL, Martin, C, Mira-Iglesias, A, Orrico-Sánchez, A, Otero-Romero, S, Rohde, G, Jodar, L, Mclaughlin, JM and Bollaerts, K

Publicada: 11 feb 2026
Resumen:
Background While multiple studies report that the BNT162b2 XBB.1.5-adapted mRNA COVID-19 vaccine (BNT162b2 XBB vaccine) is effective in preventing COVID-19 hospitalisation and death, effectiveness beyond six months remains unexplored. Methods We extended our previous study of BNT162b2 XBB vaccine effectiveness (VE) to evaluate durability against JN.1-related hospitalisation up to 46 weeks since dose using the id.DRIVE platform across Europe. This multi-country, multi-centre test-negative case-control study assessed the effectiveness and durability of the BNT162b2 XBB vaccine in preventing JN.1-associated hospitalisation among adults with severe acute respiratory infection between October 2023 and August 2024. Each case was matched with up to four controls by symptom onset date and study site. Multivariable analyses were adjusted for symptom onset date, age, sex, number of chronic conditions, and influenza vaccination receipt. Results Among 827 test-positive cases and 2232 test-negative controls, protection against hospitalisation was sustained from two to <30 weeks since dose, with evidence of significant waning thereafter. VE was 64.5% (95% CI: 56.6; 71.0) at two to <30 weeks, and 4.9% (95% CI: -30.3; 30.7) at 30 to <46 weeks. Conclusion Despite the vaccine target not matching the predominant subvariant, BNT162b2 XBB vaccine protected against JN.1-related hospitalisation for up to 30 weeks. Protection against hospitalisation was non-significant after 30 weeks since dose, potentially due to further shift in circulating SARS-CoV-2 strains and/or waning immunity. Given the high COVID-19 activity in Europe during summer 2024, an additional vaccination after six months is warranted for those at risk of COVID-19 hospitalisation to maintain year-round protection.

Filiaciones:
Volkman, HR:
 Pfizer Inc, New York, NY 10001 USA

De Munter, L:
 P95 Clin & Epidemiol Serv, Leuven, Belgium

Nguyen, JL:
 Pfizer Inc, New York, NY 10001 USA

Tran, TMP:
 P95 Clin & Epidemiol Serv, Leuven, Belgium

Mitratza, M:
 P95 Clin & Epidemiol Serv, Leuven, Belgium

Marques, C:
 Pfizer Inc, New York, NY 10001 USA

Choi, L:
 Pfizer Inc, New York, NY 10001 USA

Valluri, S:
 Pfizer Inc, New York, NY 10001 USA

Yang, JY:
 Pfizer Inc, New York, NY 10001 USA

Antón, A:
 Univ Autonoma Barcelona, Hosp Univ Vall Hebron, Vall Hebron Inst Recerca VHIR, Microbiol Dept, Barcelona, Spain

:
 Hosp Univ Germans Trias i Pujol, Carretera Canyet, Badalona, Barcelona, Spain

Conde-Sousa, E:
 P95 Clin & Epidemiol Serv, Leuven, Belgium

Drikite, L:
 P95 Clin & Epidemiol Serv, Leuven, Belgium

Grüner, B:
 Univ Hosp Ulm, Dept Internal Med 3, Div Infect Dis, Ulm, Germany

Icardi, G:
 IRCCS Policlin San Martino Hosp, Ctr Interuniv Ric Influenza & Altre Infezioni, Genoa, Italy

Ten Kate, GL:
 Univ Ziekenhuis Antwerpen, Edegem, Belgium

Martin, C:
 Le Ctr Hosp Univ St Pierre, Brussels, Belgium

Mira-Iglesias, A:
 FISABIO Publ Hlth, Vaccine Res Dept, Valencia, Spain

 Inst Salud Carlos II, Biomed Res Consortium Epidemiol & Publ Hlth CIBER, Madrid, Spain

Orrico-Sánchez, A:
 FISABIO Publ Hlth, Vaccine Res Dept, Valencia, Spain

 Inst Salud Carlos II, Biomed Res Consortium Epidemiol & Publ Hlth CIBER, Madrid, Spain

 Catholic Univ Valencia, Valencia, Spain

Otero-Romero, S:
 Univ Autonoma Barcelona, Hosp Univ Vall Hebron, Vall Hebron Inst Recerca VHIR, Prevent Med & Epidemiol Dept, Barcelona, Spain

 Univ Autonoma Barcelona, Vall Hebron Inst Recerca VHIR, Ctr Esclerosis Multiple Catalunya Cemcat, Hosp Univ Vall Hebron,Dept Neurol Neuroimmunol, Barcelona, Spain

Rohde, G:
 Goethe Univ Frankfurt, Univ Hosp, Dept Resp Med, Med Clin 1, Frankfurt, Germany

Jodar, L:
 Pfizer Inc, New York, NY 10001 USA

Mclaughlin, JM:
 Pfizer Inc, New York, NY 10001 USA

Bollaerts, K:
 P95 Clin & Epidemiol Serv, Leuven, Belgium
ISSN: 19326203





PLoS ONE
Editorial
Public Library of Science, 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 21 Número: 2
Páginas:
WOS Id: 001688314300012
ID de PubMed: 41671248
imagen Green Submitted, gold

MÉTRICAS